{
    "title": "GcMAF vs Cancer",
    "inventor_name": "Nobuto Yamamoto",
    "publication_year": 1997,
    "device_name": "GcMAF (Macrophage Activating Factor)",
    "goal": "Restore macrophage activity to treat cancer, HIV infection, and osteopetrosis by supplying the active macrophage-activating factor.",
    "problem_addressed": "Immunosuppression in cancer and HIV patients caused by loss or reduction of the Gc-protein precursor activity for macrophage activation.",
    "concept_summary": "Serum vitamin-D-binding protein (Gc protein) is a precursor that, after stepwise enzymatic treatment with beta-galactosidase and sialidase, becomes GcMAF, a potent macrophage-activating factor. Administration of minute doses of GcMAF restores phagocytic and superoxide-producing capacity of macrophages, counteracting immunosuppression observed in many cancer and HIV patients. The invention also provides assays to detect loss of precursor activity and the presence of deglycosylating alpha-N-acetylgalactosaminidase in patient serum.",
    "detailed_description": null,
    "category": "Medical & Dental Technologies",
    "principles": [
        "Enzymatic deglycosylation",
        "Macrophage activation",
        "Immune modulation",
        "Diagnostic assay for enzyme activity"
    ],
    "scientific_domains": [
        "Immunology",
        "Biochemistry",
        "Molecular Biology",
        "Oncology"
    ],
    "mechanisms_of_action": [
        "beta-galactosidase removes terminal galactose residues from Gc protein",
        "Sialidase removes sialic acid, leaving N-acetylgalactosamine as the terminal sugar",
        "Resulting GcMAF binds to macrophage receptors, enhancing phagocytosis and superoxide generation"
    ],
    "materials": [
        "Vitamin-D-binding protein (Gc protein)",
        "beta-galactosidase (immobilized)",
        "Sialidase (immobilized)",
        "Lysophosphatidylcholine (Lyso-Pc)",
        "Ammonium sulfate",
        "Citrate-phosphate buffer"
    ],
    "energy_sources": [],
    "inputs": [
        "Patient plasma/serum",
        "Recombinant or purified Gc protein",
        "beta-galactosidase",
        "Sialidase",
        "Lyso-Pc",
        "Buffers and reagents for assay"
    ],
    "outputs": [
        "Activated macrophages (increased phagocytosis, superoxide production)",
        "Diagnostic read-out of alpha-N-acetylgalactosaminidase activity",
        "Quantitative measure of MAF precursor activity"
    ],
    "claimed_performance": "Administration of as little as 10 pg per mouse (~=100 ng per human) of GcMAF produced a markedly enhanced phagocytic capacity of macrophages; in vitro treatment of monocytes from 175 cancer patients with 100 pg GcMAF / ml activated phagocytosis and superoxide generation in all samples.",
    "experimental_evidence": "Mouse studies showing enhanced macrophage activity after lyso-Pc treatment; in-vitro assays on monocytes from 175 cancer patients and 65 HIV-infected patients demonstrating activation with GcMAF; enzyme activity measurements in tumor tissue homogenates.",
    "replication_status": null,
    "keywords": [
        "GcMAF",
        "macrophage activating factor",
        "immunosuppression",
        "cancer therapy",
        "HIV therapy",
        "vitamin D binding protein",
        "beta-galactosidase",
        "sialidase"
    ],
    "related_technologies": [
        "Immunotherapy",
        "Cytokine therapy",
        "Vaccine adjuvants",
        "Diagnostic enzymology assays"
    ],
    "controversy_level": "medium",
    "confidence_score": 0.8,
    "practicability_score": 0.6,
    "fringe_score": 0.5,
    "evidence_strength": 0.6,
    "risk_score": 0.3,
    "trl_estimate": 5,
    "source_urls": [
        "http://www.thenhf.com/articles/articles_792/articles_792.htm",
        "http://www.thedcasite.com/Yamamoto/Yamamoto_biographical.html",
        "http://www.thedcasite.com/Yamamoto_file/Yamamoto.html",
        "http://www.stopcancer.com",
        "https://patents.google.com/patent/US5620846"
    ],
    "organizations": [
        "U.S. Patent Office",
        "University research groups (e.g., Cancer Research, Immunology labs)"
    ],
    "applications": [
        "Therapeutic treatment of cancer",
        "Therapeutic treatment of HIV/AIDS",
        "Treatment of osteopetrosis",
        "Adjuvant for vaccines"
    ],
    "limitations": [
        "Requires purified enzymes and controlled enzymatic steps",
        "Variable precursor activity among patients",
        "Lack of large-scale, peer-reviewed clinical trials",
        "Potential regulatory hurdles for biologic therapy"
    ],
    "open_questions": [
        "What is the long-term safety profile of repeated GcMAF dosing?",
        "How does tumor heterogeneity affect GcMAF efficacy?",
        "What are the optimal dosing regimens for different cancers?",
        "Can the diagnostic assay be standardized for routine clinical use?"
    ],
    "red_flags": [
        "Claims of \"cure\" without robust randomized clinical data",
        "Commercial products marketed without FDA approval",
        "Potential for misuse as an unproven \"miracle\" therapy"
    ],
    "evidence_quotes": [
        "\"Administration of a minute amount (10 pg/mouse; 100 ng/human) of GcMAF resulted in a greatly enhanced phagocytic capacity of macrophages.\"",
        "\"When peripheral blood monocytes/macrophages of 175 cancer patients ... were treated in vitro with 100 pg GcMAF/ml, monocytes/macrophages of all cancer patients were activated for phagocytic and superoxide generating capacity.\"",
        "\"Deglycosylation of plasma Gc protein by alpha-N-acetylgalactosaminidase ... prevents generation of MAF.\"",
        "\"Radiation therapy of cancerous lesions decreased plasma alpha-N-acetylgalactosaminidase activity with concomitant increase of precursor activity.\"",
        "\"Both alpha-N-acetylgalactosaminidase activity and MAF precursor activity of Gc protein in a patient's blood stream can serve as excellent diagnostic and prognostic indices.\""
    ]
}